Rapid Fluid Resolution and Durability With Faricimab in Neovascular Age-Related Macular Degeneration.

ABSTRACT:

Importance

In the TENAYA and LUCERNE randomized clinical trials (RCTs), approximately 80% of study participants with treatment-naive neovascular age-related macular degeneration (nAMD) achieved at least every-12-week faricimab dosing at week 112. Subsequent post hoc analyses showed more rapid drying with faricimab compared with aflibercept, 2 mg, during the initial head-to-head dosing phase (weeks 0-12).

Objective

To investigate whether rapid drying with faricimab, specifically intraretinal fluid (IRF) and subretinal fluid (SRF) resolution through week 12, is associated with later treatment durability.

Design, setting, and participants

This is a post hoc analysis of faricimab-treated study participants from the TENAYA and LUCERNE RCTs, which were randomized, double-ma

SUBMITTER: Pitcher JD 

PROVIDER: S-EPMC12921568 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature